ClinicalTrials.gg
RecruitingNCT07016360Updated Apr 29, 2026

Comparison of Efficacy of Topical Adaplene Gel Versus Crythotherapy in Recurrent Plantar Warts

A Phase 4 interventional study of Topical Adapalene Gel 0.1% and Topical Liquid Nitrogen application in Viral Warts, sponsored by Khyber Teaching Hospital. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Khyber Teaching Hospital · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Phase
Phase 4
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 12 studies in Warts with a site in Pakistan — 5 open to participants now, 5 under way, none of them phase 3. Warts · Pakistan.

Planned enrollment
4th of 12
98 · median 75
Started
2025
with 1 other
Phase 4
2 of 12
2 open now
Registered
9th of 12
by date
Lead sponsor
1 of 12
Khyber Teaching Hospital

Among the 12 studies in Warts with a site in Pakistan, this one is the 4th largest by planned enrollment, is one of 2 that started in 2025, is one of 2 in phase 4, and was the 9th registered.

By phase

12 studies; the count open now beside each. This study's row is marked.

No phase5 · 2 open
Phase 14 · 1 open
Phase 4this study2 · 2 open
Phase 21 · 0 open

By the year they started

First in 2021; this study’s year is marked. 2 started in 2025.

Size and results

Median enrollment 75 across the 12 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 12 studies in Warts with a site in Pakistan, or all of them as a file.
02

Study summary

This is a comparative study between two treatment options for skin viral infection.

Read the detailed description

This is a comparative study between two treatment for viral infection in epidermal layer of skin that proliferates slowly forming thick, growths. This study will compare and evaluate the differences in efficacy between topical liquid nitrogen and topical retinoids.

03

Conditions studied

  • Viral Warts

Browse trials for

Keywords

  • Plantar warts
  • Topical adapalene gel
  • Cryotherapy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

Patients age limit 18-60 Years Patients with either gender (Male/Female) Patients with recurrent plantar warts

Exclusion criteria

Exclusion Criteria:

  • Pregnancy/lactation. Pt on topical or systemic therapy in last 6 months. On . > 5 lesions. Pts with local secondary infections.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    A

    Treated with Topical adapalene gel 0.1%

    Drug: Topical Adapalene Gel 0.1%

  • Experimental
    B

    Treated with liquid nitrogen over affected parts

    Procedure: Topical Liquid Nitrogen application

Interventions

  • Topical adapalene is a retinoid that helps in epidermal changes. Cryotherapy is a liquid nitrogen applied to affected parts for 6 months

  • ProcedureTopical Liquid Nitrogen application

    Liquid Nitrogen will be applied to affected parts.

06

What researchers measure

Primary outcomes

  1. Efficacy of Treatment

    It will be defined through visual inspection by observing the complete clearance of the warts after 8 weeks administration of the treatment in both groups

    Time frame: 06 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Patient's confidentiality may be breached

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Feb 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
Jun 11, 2025
StartActual
Sep 15, 2025
Primary completionActual
Feb 15, 2026
CompletionEst.
Sep 15, 2026
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07016360
Lead sponsor
Khyber Teaching Hospital
Responsible party
Saba Naz (DOCTOR, Khyber Teaching Hospital) — Principal investigator
First posted
Jun 11, 2025
Start date
Sep 15, 2025
Primary completion
Feb 15, 2026
Completion
Sep 15, 2026 (estimated)
Last update
Apr 29, 2026

Study contacts

Saba Naz, MBBS
Contact
sabikhattak477@gmail.com
+923209600115
Saba Naz, MBBS
principal investigator · Khyber Teaching Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adapalene

Start the discussion